The Kru¨ppel-like zinc-finger protein GLI1 functions as a downstream transcription factor of Hedgehog signaling and plays a pivotal role in the cellular proliferation of many types of tumors, including pancreatic ductal adenocarcinoma (PDA). PDA develops from dysplastic lesions called pancreatic intraepithelial neoplasia (PanIN) through a multistep carcinogenesis process that changes its cellular characteristics, including a mucin expression profile. Increased expression of a gel-forming mucin, MUC5AC, was previously revealed as a major biomarker for the poor prognosis of PDA patients, but the molecular mechanisms responsible for its expression and correlation with poor prognosis are not fully understood. Here we show that MUC5AC is a direct transcriptional target of GLI1 in PDA cells. Overexpression of GLI1 enhanced MUC5AC expression, and a double knockdown of GLI1 and GLI2 suppressed endogenous MUC5AC expression in PDA cells. Luciferase reporter assays revealed that GLI1 and GLI2 can activate the MUC5AC promoter through its conserved CACCC-box-like cis-regulatory elements. We also found that GLI1-upregulated MUC5AC was expressed in the intercellular junction between cultured PDA cells and interfered with the membrane localization of E-cadherin, leading to decreased E-cadherin-dependent cell-cell adhesion and promoting the migration and invasion of PDA cells. Consistently, GLI1 induced the nuclear accumulation and target gene expression of b-catenin in a MUC5AC-dependent manner. Finally, immunohistochemical analysis revealed that GLI1 expression statistically correlated with MUC5AC expression and also with altered subcellular localization of E-cadherin and b-catenin in PanIN lesions and PDA. This evidence revealed a new aspect of GLI1 function in modulating E-cadherin/ b-catenin-regulated cancer cell properties through the expression of a gel-forming mucin.
Introduction
Pancreatic cancer is one of the most highly lethal tumors. Pancreatic ductal adenocarcinoma (PDA), a major histological subtype of pancreatic cancer, displays local invasion and distant metastasis during the early stages of disease, for which the current surgical therapy and chemotherapy are not so effective. Therefore, a new therapeutic strategy is required, preferably based on a better understanding of the molecular characteristics of this cancer.
Mucin is a large extracellular protein composed of a mucin core domain with heavily O-glycosylated serineor threonine-rich tandem repeat domains, which allow its polymerization and highly ordered structure. Currently, mucins are classified into membrane-associated mucins (MUC1, MUC3, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20 and MUC21), secreted gel-forming mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC19) and secreted non-gel-forming mucins (MUC7 and MUC8) by the HUGO nomenclature. Many previous studies have revealed that mucin expression profiles are a prognostic biomarker in some types of cancers Singh et al., 2008; Briggs et al., 2009) . For instance, the expressions of MUC1, MUC2 and MUC5AC were statistically associated with a shorter survival time for pancreatic cancer patients in the United States (Takikita et al., 2009) , suggesting that mucin functions not only to protect the normal epithelial surface from harsh environments but also to regulate cancer cell properties. Indeed, membrane-associated mucins were recently shown to play a crucial role in signal transduction (Schroeder et al., 2001; Jepson et al., 2002; Wen et al., 2003; Hollingsworth and Swanson, 2004; Bafna et al., 2010) . However, the role for gel-forming mucins in cancer cells is not fully understood.
One of the important signals in the development and growth of PDA is related to the secreted glycoprotein Sonic hedgehog (SHH), a mammalian homolog of Drosophila Hedgehog. Clinically, SHH and its downstream GLI transcription factors, as well as their putative target genes, are expressed in PDA and its precancerous lesion, called pancreatic intraepithelial neoplasia (PanIN) (Berman et al., 2003; Thayer et al., 2003; Prasad et al., 2005) . Experimentally, GLI1 was shown to be required for the survival and KRAS-mediated transformed phenotype of PDA cells (Nolan-Stevaux et al., 2009) . In a transgenic mouse system, the aberrant expression of a dominant-active form of GLI2 in conjunction with oncogenic KRAS in the pancreatic duct epithelium gave rise to the development of PanIN lesions and PDA (Pasca di Magliano et al., 2006) . These clinical and experimental data highlight the importance of the downstream targets of GLI transcription factors in the development and cellular properties of PDA. Prior to this study, many attempts have been made to identify the transcriptional target genes of GLIs (Yoon et al., 2002; Eichberger et al., 2006; Kasper et al., 2006) . However, whether GLIs regulate mucin expression remains unknown. To address this possibility, we focused on GLI1 to identify its target mucin gene(s) in PDA cells. Using newly established human PDA cell lines harboring either tetracycline-or estrogen-regulated expression systems, we show that the gel-forming mucin MUC5AC was directly upregulated by GLI1. In addition, we reveal that GLI1-upregulated MUC5AC attenuated E-cadherin-mediated cell-cell adhesion, promoting the migration and invasion of PDA cells. Furthermore, GLI1 induced the nuclear accumulation and target gene expression of b-catenin in a MUC5AC-dependent manner. These data show that GLI1 and its target, MUC5AC, facilitate the migration and invasion by regulating the function of E-cadherin in PDA cells.
Results

GLI1 upregulates MUC5AC expression in human PDA cell lines
We first examined the expression of mucins (the membraneassociated mucins MUC1, MUC3A, MUC3B, MUC4 and MUC12; the secreted gel-forming mucins MUC2, MUC5AC, MUC5B and MUC6; and the secreted nongel-forming mucin MUC7) in human PDA cell lines and found that the expression of MUC3B and MUC5AC correlated with that of GLI1 and GLI2 (Figure 1a ). To further investigate this correlation, we generated stable cell lines from PANC-1 cells, PANC-1 Tet/GLI1 clone 1 and clone 2. These cell lines express a high level of GLI1 upon the withdrawal of doxycycline (DOX), an analog of tetracycline, from the culture medium. Using these and their control cell lines, PANC-1 Tet/Empty clone 1 and clone 2, we found that MUC5AC but not MUC3B expression was further increased by the induction of GLI1, as evidenced by the increased expression of a known direct target of GLI1, Patched1 (PTCH) (Yoon et al., 2002) (Figure 1b and Supplementary Figures 1  and 2a ). As seen in PANC-1 cells, the transient transfection of GLI1 induced MUC5AC expression in PA-TU-8902 and PA-TU-8988T cells (Figure 1c ), which did not express any endogenous GLI1, GLI2 or MUC5AC (Figure 1a) . Conversely, we found that the endogenous MUC5AC expression in PANC-1 and SUIT-2 cells was suppressed by double knockdown of GLI1 and GLI2 (Figure 1d ). These data indicated that GLI1 upregulated MUC5AC expression and that GLI2 had a redundant role with GLI1 in the induction of Tet/GLI1 clone 1 and its control PANC-1 Tet/Empty clone 1. A full-length photo of a MUC5AC immunoblot is provided in Supplementary Figure 1. (c) RT-PCR analyses of transiently transfected PDA cells. Either EGFP-tagged GLI1 or its control EGFP expression vector was transfected into cells together with the expression vector for the puromycin-resistance gene. After selection by puromycin, RNA was extracted from the cells and subjected to an RT-PCR reaction. (d) RT-PCR (upper) and immunoblot (lower) analyses of GLI-knockdown PDA cells prepared using siRNAs. Double knockdown of GLI1 and GLI2 suppressed MUC5AC expression in PANC-1 and SUIT-2 cells. HUP-T3, which expressed endogenous GLI2 but not GLI1, did not reduce MUC5AC expression following GLI2 knockdown.
GLI1-induced MUC5AC attenuates E-cadherin S Inaguma et al MUC5AC. However, among the seven cell lines tested, the cell line HUP-T3, which expressed endogenous GLI2 but not GLI1, displayed GLI2-independent expression of MUC5AC (Figure 1d ), a phenomenon that is supposedly regulated by other transcription factor(s) (Park et al., 2008) .
MUC5AC is a direct target of GLI1 GLI1 has been reported to control the expression of many downstream target genes, either directly or indirectly (Yoon et al., 2002; Eichberger et al., 2006; Kasper et al., 2006) . To determine whether MUC5AC is a direct target of GLI1, we next generated two stable cell lines, PANC-1 GLI1ER and its control PANC-1 ER . PANC-1 GLI1ER cells express a chimeric transgene composed of an enhanced green fluorescent protein (EGFP)-tagged version of the amino-terminal half of GLI1, including its zinc-finger DNA-binding domain, fused to the AF2 domain of the mouse estrogen receptor 1 (Esr1) cDNA, whereas PANC-1 ER cells harbor only EGFP-tagged AF2 domain (Figure 2a) . Therefore, only the former was expected to quickly upregulate GLI1 target genes following b-estradiol (E2) treatment. Using these cell lines, we first analyzed a time course of induction of known target genes. We found a rapid induction of PTCH as early as 3 h after the treatment with E2, whereas JAG2, another target of GLI1 , was induced by 24 h after treatment (Figure 2b , left), indicating that JAG2 may serve as an indirect target in our experimental system. We then examined MUC5AC expression in these cells and found that it was GBS1 and GBS2 (GBS1mut and GBS2mut: insert) are indicated by an X in the reporter vectors. Columns, means of three independent experiments; bars, s.d.; *Po0.01. (e) Chromatin immunoprecipitation (ChIP) assay using PANC-1 cells transiently transfected with the indicated vectors. ChIP PCR fragments (first and third columns) cover both GBS1 and GBS2 of MUC5AC and two GBSs of the PTCH gene. As a control, 0.5% of the input (second and fourth columns) was analyzed. RT-PCR and immunoblot analyses are also shown to estimate the expression and transcriptional activity of Halo-GLI1.
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S Inaguma et al upregulated after 3 h of treatment with E2 in PANC-1 GLI1ER cells but not in PANC-1 ER cells. Furthermore, pretreatment with the protein synthesis inhibitor cycloheximide did not block the E2-induced upregulation of MUC5AC in PANC-1 GLI1ER cells (Figure 2b , right). These data indicated that MUC5AC is a direct target gene of GLI1.
GLI1 activates the MUC5AC promoter
Previous analyses of the human MUC5AC gene identified the transcriptional start site and structural properties of the promoter that lies within 1.3 kb of the 5 0 flanking region from the translational start codon (ATG: nucleotide position þ 48 to þ 50) (Supplementary Figure 3a ) (Li et al., 1998) . In this region, we found two putative GLI-binding sites (GBSs) localized between À73 and À64 (5 0 -GCCCACCCAC-3 0 : GBS1) and between À121 and À112 (5 0 -GAGCACCCAC-3 0 : GBS2). These sites contained a CACCC sequence, which is a target sequence of the Kru¨ppel-like zinc-finger proteins and is conserved across species (Supplementary Figure 3b) . To address whether GLI proteins activated the MUC5AC promoter through these GBSs, we generated luciferase reporter constructs containing 1 kb or shorter fragments of the human MUC5AC promoter region and examined their responsiveness to GLI1 and GLI2 using luciferase reporter assays ( Figure 2c ). In transiently transfected PANC-1 and HEK293T cells, we found that either GLI1 or GLI2 induced the activation of the reporter constructs containing the À951 to þ 47, À529 to þ 47, À179 to þ 47 and À109 to þ 47 fragments of the human MUC5AC promoter region. The construct containing the À61 to þ 47 fragment did not respond to GLIs. We then introduced mutations (GBS1mut and GBS2mut: Figure 2d , insert) into the GBSs of the reporter construct containing the À529 to þ 47 fragment and examined the GLI responsiveness of these mutant constructs ( Figure 2d ). Our results suggested that both GBSs can respond to GLIs. Finally, we performed chromatin immunoprecipitation assays using transiently transfected PANC-1 cells with a Halo-tagged GLI1 expression vector. We found that the GBS-containing fragment of the MUC5AC gene co-precipitated with GLI1 to a similar extent as did the GBS fragment found in the PTCH gene (Figure 2e ), supporting the possibility that GLI1 directly activates the MUC5AC promoter through its GBS.
GLI1-upregulated MUC5AC destabilizes E-cadherin
The reduction or loss of membranous E-cadherin expression promotes the migration and invasion of cancer cells in association with the nuclear accumulation of b-catenin. Given the finding that MUC5AC expression correlated with a poor prognosis in PDA patients (Takikita et al., 2009) , we postulated that GLI1-induced MUC5AC might be involved in the regulation of E-cadherin and b-catenin. RT-PCR and immunoblot analyses of sparsely cultured PANC-1 Tet/GLI1 clone 1 cells revealed that endogenous and GLI1-upregulated MU-C5AC were effectively knocked down by either of two small interfering RNAs (siRNAs) for MUC5AC: siMU-C5AC-1 and siMUC5AC-2 (Figure 3a , upper five columns, and Supplementary Figure 2b) . In this sparse culture condition, neither DOX treatment nor MUC5AC knockdown changed the levels of E-cadherin protein or mRNA (Figure 3a , middle four columns), indicating that neither GLI1 nor MUC5AC per se modulated E-cadherin expression. However, in a confluent culture, the amount of E-cadherin protein was reduced by DOX withdrawal, but was in turn increased by MUC5AC knockdown, whereas 
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E-cadherin mRNA levels were not significantly changed by either treatment (Figure 3a , lower four columns). In normal epithelial cells, E-cadherin is expressed and stabilized on the cell membrane by a Ca 2 þ -dependent trans-homophilic ligation, the loss of which leads to the destabilization of E-cadherin protein. Indeed, we found that PANC-1
Tet/GLI1 clone 1 cells in culture medium lacking DOX expressed MUC5AC in the intercellular junction of the cells (Figure 3b) , and that MUC5AC knockdown led to the reconstitution of the membrane localization of E-cadherin (see Figure 5a , below), suggesting that GLI1-upregulated MUC5AC interferes with the membrane localization and stability of E-cadherin protein in confluent cells.
GLI1-upregulated MUC5AC attenuates E-cadherinmediated intercellular adhesion and facilitates migration and invasion of PDA cells
We next assessed the strength of cell-cell adhesion using a cell-dissociation assay. We found that DOX withdrawal reduced the cell-cell adhesion of control siRNA-treated PANC-1 Tet/GLI1 cells, whereas MUC5AC knockdown increased the adhesion in either DOX-treated or DOXwithdrawn PANC-1
Tet/GLI1 cells (Figure 4a , left, and Supplementary Figure 5a ). This MUC5AC knockdowninduced increase in adhesion was reduced to the level of control siRNA-treated PANC-1 Tet/GLI1 cells by additional treatment with an anti-E-cadherin-saturating antibody (Figure 4a, right) . These data suggested that GLI1-upregulated MUC5AC interfered with the E-cadherin-mediated cell-cell adhesion of PDA cells. We then examined whether GLI1-upregulated MU-C5AC modulates cell migration and invasion. A woundhealing assay revealed that DOX withdrawal increased the migration of control siRNA-treated PANC-1 Tet/GLI1 cells, whereas MUC5AC knockdown reduced migration (Figures 4b and c, left, and Supplementary Figure 5b) . The Boyden chamber invasion assay also revealed (Figure 4d , left, and Supplementary  Figure 5c ). In agreement with the cell-dissociation assay, MUC5AC knockdown-induced reductions in migration and invasion were recovered to the levels of control cells by blocking the function of E-cadherin with an anti-Ecadherin-saturating antibody (Figures 4c and d, right) . As PANC-1
Tet/GLI1 cells did not express the other gel-forming mucins (MUC2, MUC5B, MUC6 and MUC19) (Supplementary Figure 4) , we concluded that GLI1-induced MUC5AC is responsible for the migration and invasion by E-cadherin inhibition.
GLI1 modulates the subcellular localization and target gene expression of b-catenin through MUC5AC
We next examined whether GLI1-upregulated MU-C5AC changed the subcellular localization of b-catenin. The DOX-withdrawn PANC-1 Tet/GLI1 clone 1 cells were treated with either siControl-1 or siMUC5AC-1 and stained with E-cadherin and b-catenin antibodies (Figure 5a ). Both siControl-1-and siMUC5AC-1-treated cells displayed a cytoplasmic localization of E-cadherin and nuclear accumulation of b-catenin under sparse culture conditions (data not shown). However, siMUC5AC-1-treated confluent PANC-1
Tet/GLI1 cells exhibited the membranous E-cadherin and b-catenin expression, whereas siContriol-1-treated confluent PANC-1 Tet/GLI1
showed the same E-cadherin and b-catenin expression pattern as did sparsely cultured cells (Figure 5a , top two columns). Consistent with this observation, DOX-withdrawn PANC-1
Tet/GLI1 clone 1 cells displayed an increased expression of the b-catenin target genes CCND1 (Cyclin D1) and FGF18 (Shtutman et al., 1999; Shimokawa et al., 2003) , which were blocked by siMUC5AC-1 treatment (Figure 5b ). Furthermore, a double knockdown of GLI1 and GLI2, and also a single knockdown of MUC5AC enhanced the membrane localization of E-cadherin and b-catenin in parental PANC-1 cells, as observed in PA-TU-8902 cells that did not express GLIs or MUC5AC (Figure 5a , bottom four columns). These data indicated that GLI1 increased the nuclear accumulation and target gene expression of b-catenin through the MUC5AC-mediated abrogation of E-cadherin-based intercellular adhesion in PDA cells.
GLI1 expression correlates with increased MUC5AC expression and altered E-cadherin/b-catenin localization in PanIN and PDA Finally, to demonstrate that GLI1 upregulates MU-C5AC in vivo, we examined the expression of GLI1, MUC5AC, E-cadherin and b-catenin in human PanIN 
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lesions and in PDA by immunohistochemistry (representative photos in Figure 6a ; statistical results in Supplementary Table 1 ). GLI1 and MUC5AC were not expressed in the normal duct. GLI1 expression was detected at low levels in low-grade PanIN (PanIN-1A and PanIN-1B) and increased in high-grade PanIN (PanIN-2 and PanIN-3) and in PDA. MUC5AC expression was faintly detectable in low-grade PanIN but increased in high-grade PanIN and in PDA (Figure 6a ). Using a semi-quantitative scoring of the staining intensity on a three-tiered scale (negative, 0; weak, 1; strong, 2), the GLI1 and MUC5AC expression levels in PanIN lesions and in PDA were statistically increased compared with those in the normal duct epithelium (Supplementary Table 1a and b) . Spearman's rank correlation analysis also revealed a positive correlation between GLI1 and MUC5AC expression (R ¼ 0.741, Po0.0001) (Supplementary Table 1c) . In agreement with a previous report (Al-Aynati et al., 2004) , the normal pancreatic duct epithelium displayed the membrane localization of E-cadherin and b-catenin, whereas PanIN-3 and PDA cells showed a reduction or loss of membrane localization of E-cadherin and an increased nuclear accumulation of b-catenin (Figure 6a) , which statistically correlated with GLI1 expression (Figure 6b ). This evidence supported our in vitro results using cultured PDA cells showing that GLI1-induced MUC5AC altered the subcellular localization of E-cadherin and b-catenin.
Discussion
It has previously been hypothesized that MUC5AC expression is upregulated by the SRY-related HMG box protein SOX2, based on the correlated expression of SOX2 and MUC5AC in gastric cancer (Park et al., 2008) . However, SOX2 expression was not correlated with MUC5AC in PanIN and in PDA (Sanada et al., 2006) , suggesting that unknown mechanism(s) might be involved in MUC5AC expression during pancreatic carcinogenesis. In this study, we provide the first evidence identifying a gel-forming mucin, MUC5AC, as a direct transcriptional target of GLI1 in PDA cells. Furthermore, the correlation in the expression levels of GLI1 and MUC5AC in PanIN in our study supports the notion that GLI1 upregulates MUC5AC expression during pancreatic carcinogenesis.
Many GLI1 target genes have been identified using rat kidney cells (Thayer et al., 2003) , epidermal cells and basal cell carcinoma cells (Eichberger et al., 2006) ; however, no mucin genes were identified in these studies. We currently do not have a full understanding of why previous attempts have failed to identify MUC5AC as a GLI1 target gene. MUC5AC, along with MUC2, MUC5B and MUC6 genes, is clustered within a 400-kb-long region of human chromosome 11 (11q15), which is known as a hot spot for abnormal methylation in cancer. Indeed, Vincent et al. reported that MUC2 and MUC5B expressions were epigenetically regulated in gastrointestinal cancer cells and in PDA cells. They also showed that MUC5AC expression was rarely influenced by epigenetic mechanisms (Vincent et al., 2007) ; however, the possibility remains that MUC5AC is epigenetically silenced in other cell types, such as those previously used for GLI1 target gene identification.
Recently, the roles of membrane-associated mucins in cancer cells have been revealed. For instance, a fragment of the MUC1 cytoplasmic tail is cleaved and transported into the nucleus in association with b-catenin, affecting its function as a co-activator for TCF/LEF1 (Wen et al., 2003) . Both MUC1 and MUC4 also associate with ErbB tyrosine kinase receptors on the cell membrane and enhance the downstream mitogen-activated protein Figure 6 Immunohistochemical analysis of GLI1, MUC5AC, E-cadherin and b-catenin in PanIN and PDA. (a) GLI1 and MUC5AC expression was evaluated by staining intensity and was semi-quantitatively scored (negative, 0; weak, 1; strong, 2), as indicated in the photos. Statistical analyses are provided in Supplementary Table 1 . E-cadherin and b-catenin expressions in the marked area are presented. The normal duct epithelium and PanIN-1A and 1B displayed membranous expression of E-cadherin and b-catenin, whereas PDA cells showed reduced membranous expression of E-cadherin and increased nuclear accumulation of b-catenin. Bar, 50 mm. (b) Correlation between GLI1 expression and altered subcellular localization of E-cadherin and b-catenin. 'Abnormal' expression of E-cadherin includes the reduction or loss of E-cadherin expression.
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S Inaguma et al kinase signaling pathway (Schroeder et al., 2001; Jepson et al., 2002) . However, despite the fact that increased MUC5AC expression correlates with a worse prognosis for patients with lung adenocarcinoma (Yu et al., 1996 (Yu et al., , 2005 , cholangiocarcinoma (Boonla et al., 2003; Aishima et al., 2006) and PDA (Takikita et al., 2009 ), a molecular mechanism for MUC5AC in determining the properties of these cancer cells has not been fully elucidated. In this study, we showed that GLI1-upregulated MUC5AC facilitates the migration and invasion of PDA cells through the attenuation of E-cadherin-mediated intercellular adhesion. In addition, we showed that GLI1 is involved in b-catenin nuclear accumulation and target gene expression through MUC5AC upregulation. These results reveal a new link between GLI1 and E-cadherin/b-catenin signaling, and this interaction might mechanistically account for the fact that MUC5AC is a biomarker for poor prognosis in PDA patients. Indeed, Truant et al. previously reported that MUC5AC attenuated E-cadherin-mediated cellcell adhesion in human colon cancer HT29 cells (Truant et al., 2003) , which supports our present study. Does this finding mean that MUC5AC per se promotes the malignant behavior of cancer cells? We think this unlikely because MUC5AC knockdown did not change the expression (and subcellular localization) of E-cadherin and b-catenin in sparsely cultured PDA cells. Rather, MUC5AC expressed in the intercellular junction between confluent PDA cells was likely responsible for the inhibition of homophilic ligation and stabilization of E-cadherin on the cell membrane. Indeed, MUC5AC is highly expressed on the apical/ luminal side of the normal stomach epithelium and is not correlated with a worse prognosis for gastric cancer patients (Lee et al., 2001) . Therefore, we propose the possibility that the MUC5AC-mediated dysfunction of E-cadherin depends on either impaired apical sorting or increased lateral sorting of MUC5AC in PDA cells (and potentially also in lung adenocarcinoma and cholangiocarcinoma), a sorting mechanism that might typically be maintained in the normal stomach epithelium and in gastric cancer cells. On the basis of this possibility, we hypothesize a role for GLI1 in attenuating the function of E-cadherin during pancreatic carcinogenesis as follows. GLI1 expression is induced in the pancreatic duct epithelium of low-grade PanIN, in which MU-C5AC is not yet expressed. Following either oncogenic activation of KRAS signaling (Pasca di Magliano et al., 2006; Kasai et al., 2008) or stimulation with Hedgehoginduced stromal factors (Yauch et al., 2008; NolanStevaux et al., 2009) , GLI1 is derepressed from a pivotal suppressor of GLI proteins, Suppressor-of-Fused, and is consequently activated enough to induce the MUC5AC gene in high-grade PanIN. The abnormal lateral sorting of MUC5AC by an unknown mechanism abrogates the membrane localization and stabilization of E-cadherin, leading to the reduction or loss of membrane E-cadherin and the nuclear accumulation of b-catenin, which facilitates the migration and invasion of PDA cells.
Finally, we propose the possibility that MUC5AC could be a potential therapeutic target. MUC5AC knockdown or breakdown of the polymerized MUC5AC gel structure might restore the E-cadherin-mediated intercellular adhesion and the downregulation of b-catenin signaling, preventing the migration and invasion of PDA cells. This possibility should be investigated in future studies.
Materials and methods
Cells
Human PDA cell lines were obtained from the RIKEN BioResource Center (Tsukuba, Japan), the Health Science Research Resources Bank, the Japan Health Sciences Foundation (Sennan, Japan) and the German Collection of Microorganisms and Cell Cultures (DSMZ) (Braunschweig, Germany). PANC-1
Tet/GLI1 clone 1 and clone 2 stable cell lines capable of human GLI1 expression and their control PANC-1 Tet/Empty clone 1 and clone 2 cell lines were established using a tetracycline-regulated (Tet-off) system (Clontech, Mountain Veiw, CA, USA) according to the manufacturer's protocol. DOX was used as a chemical to regulate the Tet-off system (Clontech). PANC-1 GLI1ER cell line was established by stable transfection with an expression vector containing the EGFPtagged amino-terminal half of mouse GLI1 cDNA fused to the ligand-dependent transactivation functional domain (AF2) of the mouse estrogen receptor 1 (Esr1), whereas the PANC-1 ER cell line only harbored the EGFP-tagged AF2 domain. E2 (Sigma, St Louis, MO, USA) was used at 10 nM to stimulate PANC-1 GLI1ER and PANC-1 ER cells.
Luciferase reporter assays, immunoblots and RT-PCR
The human MUC5AC promoter region was PCR amplified and cloned into a firefly luciferase reporter vector, pGL4-basic (Promega, Madison, WI, USA). GBS1mut and GBS2mut, mutants for putative GBSs (GBS1 and GBS2) in the MUC5AC promoter, were generated using the GeneTailor Site-Directed Mutagenesis System (Invitrogen, Carlsbad, CA, USA). Luciferase reporter assays were carried out using a Dual-Glo Luciferase Assay System (Promega) as described previously (Kasai et al., 2004 (Kasai et al., , 2008 . The following Stealth RNAi siRNAs (Invitrogen) were used to knock down GLI1 and GLI2: for GLI1 (siGLI1), 5 0 -AAUGCAAGGUCCCUC GUCCAAGCUG-3 0 , 5 0 -CAGCUUGGACGAGGGACCUUG CAUU-3 0 and for GLI2 (siGLI2), 5 0 -CAUAGAUGACCAC CUCAGCCUCCUG-3 0 , 5 0 -CAGGAGGCUGAGGUGGUCA UCUAUG-3 0 . Negative Universal Control of Stealth RNAi (Invitrogen) was used as a control (siControl). To knock down MUC5AC and b-catenin, 21-nucleotide duplex siRNAs were synthesized as follows: siMUC5AC-1, 5 0 -CGGAGACUGC GAGUACACGTT-3 0 and 5 0 -CGUGUACUCGCAGUCUCC GTT-3 0 ; siMUC5AC-2, 5 0 -CUAUGAGAUCCGCAUCCAG TT-3 0 and 5 0 -CUGGAUGCGGAUCUCAUAGTT-3 0 ; and sib-catenin, 5 0 -GGAUGAUCCUAGCUAUCGUTT-3 0 and 5 0 -ACGAUAGCUAGGAUCAUCCTT-3 0 . The following duplexes were used as controls: siControl-1, 5 0 -CGUACGCG GAAUACAACGATT-3 0 and 5 0 -UCGUUGUAUUCCGCG UACGTT-3 0 and siControl-2, 5 0 -CGCGAAACGAACGAAU AAATT-3 0 and 5 0 -UUUAUUCGUUCGUUUCGCGTT-3 0 . Immunoblot and semi-quantitative RT-PCR analyses were performed as described previously (Kasai et al., 2004 (Kasai et al., , 2008 . RNAs isolated from normal human tissues (the trachea, stomach, small and large intestine, gallbladder, pancreas and prostate: BioChain, Hayward, CA, USA) were combined, reverse-transcribed either with or without reverse transcriptase GLI1-induced MUC5AC attenuates E-cadherin S Inaguma et al and used as a template for the control RT-PCR (Control RT þ or Control RTÀ).
Chromatin immunoprecipitation assays PANC-1 cells were transiently transfected with a Halo-tagged GLI1 expression vector, a Halo-tag expression vector or a mock vector. After a brief cross-linking with formaldehyde, cell lysates were served to co-precipitation with HaloLink Resin (Promega) according to the manufacturer's protocol. Chromatin immunoprecipitation primers were designed to amplify a fragment containing both GBS1 and GBS2 of the MUC5AC gene and also a fragment containing two GBSs of the PTCH gene (Agren et al., 2004) Cell-dissociation, wound-healing and invasion assays Cell-dissociation assays were performed as reported previously (Gkretsi et al., 2005) . For wound-healing assays, siRNAtreated PANC-1
Tet/GLI1 cells were cultured either with or without DOX and scratched using pipet tips. The wound was measured 18 h after scratching. Invasion assays were performed using BioCoat Matrigel Invasion Chamber (BD Biosciences, Bedford, MA, USA) according to the manufacturer's protocol. In brief, siRNA-treated PANC-1
Tet/GLI1 cells were cultured either with or without DOX, and 5 Â 10 4 cells were transferred to the chamber. Fetal bovine serum (10%) was used as a chemoattractant. After 22 h of incubation, the invaded cells were fixed, stained and counted. To estimate E-cadherin-mediated cell-cell adhesion, 2 mg/ml of anti-Ecadherin-saturating antibody (clone ID SHE78-7, Takara Bio Inc., Ohtsu, Japan) was used.
Immunohistochemistry and statistical analysis
From the archives of the Department of Pathology at the Aichi Medical University Hospital, 27 cases of PDA were selected for study based on the availability of tissue samples. Sample use was approved by the Institutional Ethical Review Board. Serial sections from formalin-fixed, paraffin-embedded tissue samples were subjected to hematoxylin and eosin (H&E) staining and immunohistochemical staining. The staining intensities of GLI1 and MUC5AC were semi-quantitatively scored using a three-tiered scale and compared using a Mann-Whitney U test. The correlations between GLI1 and MUC5AC expression and those between GLI1 expression and the subcellular localization of E-cadherin/b-catenin were examined using Spearman's correlation coefficient. P-values of o0.05 were considered statistically significant. StatView 5.0 (SAS Institute Inc., Cary, NC, USA) was used for statistical analyses.
Immunofluorescence staining and confocal laser scanning microscopy Cells were plated onto fibronectin-coated coverglass (BD Biosciences) and fixed either with Carnoy's fluid (75% ethanol, 25% glacial acetic acid) to examine MUC5AC expression (Figure 3b ) or with 4% paraformaldehyde for the other immunofluorescence staining (Figure 5a ). Cells were then used for immunofluorescence staining as reported previously (Kasai et al., 2004 (Kasai et al., , 2008 . Z-stack confocal fluorescence images were obtained using an LSM710 fluorescence confocal microscope (Carl Zeiss MicroImaging, Goettingen, Germany) under a 40 Â water immersion lens.
